Corporate Information

message

ceo

Kyoto Drug Discovery & Development: 10 Years of Progress

At Kyoto Drug Discovery & Development, we remain steadfast in our mission: to be a true drug discovery company—now and in the future.

Drug discovery companies and pharmaceutical companies play distinct yet complementary roles. Drug discovery companies like ours are rooted in science and innovation. We identify unmet medical needs, envision therapeutic possibilities, and chart the course toward clinical validation. In contrast, pharmaceutical companies focus on delivering approved medicines to patients through large-scale manufacturing, distribution, and ongoing safety assurance.

We contribute to society through Drug Discovery & Development. For patients facing serious, untreatable diseases, we search for promising compounds, refine them through rigorous science, and guide them step by step toward becoming real-world treatments.

This year marks our 10th anniversary. The therapies we are developing continue to progress steadily, bringing us closer to making a real impact in patients’ lives.

Every member of our team shares a deep passion for creating treatments for diseases with no current cure. As a drug discovery company, we take our social responsibility seriously and are sincerely grateful for the support and collaboration of the academic, medical, and broader communities.

With unwavering commitment, we will continue our efforts to bring hope and healing through innovation.

代表取締役 武蔵国弘

management

We at Kyoto Drug Discovery & Development Co., Ltd. discover innovative bio-seeds from fundamental research throughout the world, We conduct drug discovery and development and contribute to the development of treatments for incurable diseases with a focus on ophthalmology.
We are dedicated to bringing smiles to patients around the world.

company

Corporate name Kyoto Drug Discovery & Development Co., Ltd.
Head Office 8F , DP Square Sakaisuji Honmachi 1-6-9 , Awaji-Machi , Chuo-ku , Osaka , 541-0047 JAPAN
Labo #302, Saito Bio Hills Center 7-7-18,Saitoasagi,Ibaraki-city,Osaka,567-0085 JAPAN
President & CEO Kunihiro Musashi
Subsidiary KDDD Inc.
3675 MARKET ST STE 200 PHILADELPHIA,PA 19104,U.S.A
Major Business Activities Research and Development of Drug, Diagnostic Drug, Human Cell Therapy and Gene therapy Products, Medical Equipment, Medical Instruments, Reagent and Medical Supplies
Establishment May 15th. 2015
Account Closing Month April
Capital 69.6 million yen(as of April 30, 2022)
Our Bank Bank of Tokyo-Mitsubishi UFJ, Toji Branch Sumitomo Mitsui Banking Corporation, Kyoto Branch

history

April 1st, 2023

Adopted for AMED Pre-Orphan Project

February 17th, 2022

Lab moves into Saito Bio Hills Center

July 15th, 2021

Headquarters moves into Chuo-ku, Osaka

August 1st, 2017

Labo was established in a building in Kyoto University

September 27th, 2016

Headquarters moves into a building in Kyoto University

March 30th, 2016

License Agreement with Kyoto University

May 15th, 2015

Established

officer

CEO Kunihiro Musashi
M.D. Ph.D.
CTO Masaki Okamoto
Ph.D.
Director, General Manager Research and Development Dept Nobuaki Miyawaki
Ph.D.
Auditor Shinichi Kotani

about kus

KUSs, Kyoto University Substances, are valosin-containing protein (VCP) modulators. They ameliorated abnormally low ATP levels by inhibiting the ATPase of VCP, thereby protected cells from degeneration and death. Several reports were provided that KUSs have neuroprotective effects that protect retinal nerve fibers and retinal ganglion cells on animal models. The facts may contribute to deterioration restraint of glaucoma. Glaucoma is a leading cause of vision loss worldwide. Lowering intraocular pressure by drugs and/or surgery is the only evidence-based treatment of glaucoma. We believe that KUSs will be able to provide convenient novel therapeutics for neuroprotection in incurable eye diseases such as glaucoma. KUSs may also provide novel strategy for cell protection in other areas.

Development Pipeline